Apogee Therapeutics

• The moderate to severe atopic dermatitis market is experiencing significant growth with 45+ companies developing over 50 pipeline therapies, driven by rising global prevalence and increased awareness of the condition. • Recent advancements include promising biologics like rezpegaldesleukin (granted FDA fast-track designation), JAK inhibitors such as VC005 and QY201, and novel mechanisms targeting IL-4/IL-13 pathways, offering new hope for patients with inadequate response to current treatments. • Key players including Nektar Therapeutics, Corvus Pharmaceuticals, and Apogee Therapeutics are advancing clinical trials with significant milestones expected in late 2025, potentially transforming the therapeutic landscape for this chronic inflammatory skin condition.

APG777, Apogee Therapeutics' investigational antibody for atopic dermatitis, demonstrated favorable safety profile and extended half-life in Phase 1 healthy volunteer study.

Apogee Therapeutics will announce interim results from its Phase 1 healthy volunteer trial of APG990, advancing their portfolio of novel biologics for inflammatory and immunology conditions.

Apogee Therapeutics has dosed the first patient in Part B of the Phase 2 APEX trial for APG777, targeting moderate-to-severe atopic dermatitis.

Apogee Therapeutics announced positive Phase 1 interim data for APG777, a novel IL-13-targeting monoclonal antibody with an extended 75-day half-life for atopic dermatitis treatment.